Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07517198 · ClinicalTrials.gov registry record · Phase 1
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
A Phase 1 study, sponsored by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT07517198 is a Phase 1 study that is actively recruiting participants, run by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT07517198, a Phase 1 study, is actively recruiting participants, sponsored by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
Interventions
- DRUG EXS74539
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-04-13 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07517198
The ClinicalTrials.gov registry entry for NCT07517198 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EXS74539 is the first listed.
NCT07517198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07517198 about?
NCT07517198 is a clinical study titled "Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors". The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
What is the current status of trial NCT07517198?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2026-04-13. Estimated completion is 2029-03.
What interventions are being tested in trial NCT07517198?
The interventions under investigation include: EXS74539 (DRUG).
Who is sponsoring clinical trial NCT07517198?
This trial is sponsored by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.